



## **Bioxodes to present first-in-class drug candidate BIOX-101 for hemorrhagic stroke to investors and pharmaceutical community in range of conferences**

**Gosselies (Belgium), 20 February 2024** – Bioxodes SA, a biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces today that it will present the latest insights in its corporate development and progress in Phase 2a testing of its lead candidate BIOX-101 (Ir-CPI) for hemorrhagic stroke, at a series of conferences with investors and the pharmaceutical and medical communities across Europe in the coming weeks.

Chief Executive Officer Marc Dechamps will take part in a panel discussion entitled “Investing in start-ups for a greener, healthier and digital Europe” at the 2024 EIT Summit in Brussels today, together with Mark Boris Andrijanic, member of the Governing Board of the European Institute of Innovation and Technology (EIT), as well as Vice President International Markets of technology company Kumo.AI, Alessandro Tappi, Chief Investment Officer at the European Investment Fund (EIF), and Caroline Viarouge, CEO of EIT Manufacturing. In the coming weeks, he will present Bioxodes at the following events:

- The 17<sup>th</sup> **Annual European Life Sciences CEO Forum**, organized by Sachs Associates, in Zurich, Switzerland, where Mr Dechamps will speak on 28 February, at 4:10 pm CET.
- The 10<sup>th</sup> **LSX World Congress** for Biotech, Healthtech and Medtech in London, 29/30 April.
- The 24<sup>th</sup> **BioEquity Europe** conference in San Sebastián, Spain, on 14 May.

“Hemorrhagic stroke is responsible for 40% of all stroke-related deaths, and there is currently no indicated therapy on the market. It is a disease with a poor prognosis for patients, and I am excited to present our first-in-class drug candidate BIOX-101 to investors and members of the pharmaceutical community over the coming weeks,” Bioxodes Chief Executive Officer Marc Dechamps said.

The active ingredient in BIOX-101 is a sequence of a protein identified in the saliva of the tick (*Ixodes ricinus*), which prevents the formation of blood clots without increasing the risk of bleedings. By inhibiting neutrophils activation, it also prevents the acute neuroinflammatory events associated with intracerebral hemorrhage. BIOX-101 is for use in patients within the first 12 hours of a stroke and is in Phase 2a clinical testing in a randomized open-label proof-of-concept study among 32 patients in Belgium.



### **About Bioxodes**

Bioxodes is a biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, Bioxodes has developed its lead asset BIOX-101, based on the Contact Phase Inhibitor molecule Ir-CPI. BOX-101 is a first-in-class drug candidate aimed at patients with thrombo-inflammatory disease. The company, which is based in Gosselies in Belgium, has so far secured €34 million in funding from Belgian investment funds and business angels, including €8.5 million in non-dilutive funding from the Wallonia region. Worldwide, Bioxodes holds both granted and pending patents associated with Ir-CPI.

[www.bioxodes.com](http://www.bioxodes.com)

### **For more information please contact:**

#### HEAD OFFICES

Parc d'activités Aéroport  
Rue Santos-Dumont, 1  
6041 Gosselies, Belgium

[investment@bioxodes.com](mailto:investment@bioxodes.com)

+32 496 590354

#### Media Relations

Alexandra Schiettekatte

[alexandra.alicato@outlook.com](mailto:alexandra.alicato@outlook.com)

+32 476 65 0438